Neurological Disease

Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain.

NXN-188 is a combined nNOS inhibitor and an agonist of 5HT-1B/1D receptor. NXN-188 can be studied in research on migraine.

A-3190 is an orally active, blood-brain barrier permeable CD38 inhibitor, with an IC₅₀ of 7.25 nM against human CD38 and 1.24 nM against mouse CD38. A-3190 is a derivative of A-8531 (HY-184021), and it forms covalent adducts with NAD⁺ in the presence of CD38. A-3190 acts as an inducer of NAD⁺ levels and an inhibitor of NAM and ADPR levels. A-3190 increases NAD⁺ levels in the skin, lung, liver and brain of rodents, while reducing NAM and ADPR levels in brain tissues. A-3190 can be used in research related to multiple sclerosis, Parkinson's disease and Alzheimer's disease.

(N-Me-Tyr1,N-Me-Arg7,D-Leu-NHEt8)-Dynorphin A (1-8) (E-2078), a stable Dynorphin A (1–8) (HY-P2159) analog, is a kappa opioid receptor (KOR) agonist.

AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of AChE/BChE (AChE IC50 = 0.96 ± 0.14 µM, BChE IC50 = 1.23 ± 0.23 µM). AChE/BChE-IN-2 has the potential for the research of AD diseases.

(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC₅₀ value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases.

Acesulfame potassium (Standard) is the analytical standard of Acesulfame potassium (HY-D0195). This product is intended for research and analytical applications. Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion.

AVLX-125 (UCCB01-125) is a PSD-95 and PDZ domain inhibitor with K_d value of 10 nM. AVLX-125 can be used in the study of inflammatory pain.

Z6466608628 hydrochloride is a selective PPIL4 molecular glue degrader with human PPIL4 EC₅₀ values of 0.34 µM. Z6466608628 hydrochloride functionally recruits PPIL4 to CRBN, induces CRL4^CRBN-mediated ubiquitylation and degradation of PPIL4. Z6466608628 hydrochloride can be used for the research of intracranial aneurysms^[1].

Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC₅₀ values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease.

MTIC-¹³C is the ¹³C-labeled MTIC (HY-119696). MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity

CP-99994 hydrochloride is a Tachykinin neurokinin 1 (NK-1) receptor antagonist with a K_i of 0.25 nM. CP-99994 hydrochloride prevents colorectal sensitization in the context of visceral hypersensitivity. CP-99994 hydrochloride reduces colorectal hypersensitivity induced by acetic acid injections in a model of bladder-colon cross-sensitization. CP-99994 hydrochloride attenuates the neuroglial interactions and MAPK-p38 phosphorylation associated with visceral hypersensitivity.

BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease.

SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC₅₀ = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.

Neuropeptide SF (mouse,rat) is a potent neuropeptide FF receptor agonist with K_i values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .

Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects.

m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and dopaminergic receptor^{[1, 2]}.

AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research.

N-Despropyl Ropinirole (SKF-104557) is an active metabolite of the dopamine D2 receptor agonist Ropinirole (HY-B0623). N-Despropyl Ropinirole is a full agonist at human D2 and D3 receptors. N-Despropyl Ropinirole is a partial agonistof the hD4 receptor.

Palonosetron-d₃ hydrochloride is the deuterium labeled Palonosetron hydrochloride (HY-A0021). Palonosetron hydrochloride is a 5-HT3 antagonist primarily used to prevent acute, delayed, and overall chemotherapy-induced nausea and vomiting. In addition, Palonosetron hydrochloride exhibits moderate anti-flavivirus activity and potent anti-Zika virus activity in mammalian cells. Palonosetron hydrochloride also possesses antidepressant activity.